Literature DB >> 9673275

Paromomycin and geneticin inhibit intracellular Cryptosporidium parvum without trafficking through the host cell cytoplasm: implications for drug delivery.

J K Griffiths1, R Balakrishnan, G Widmer, S Tzipori.   

Abstract

Cryptosporidium parvum, which causes intractable diarrhea and lethal wasting in people with AIDS, occupies an unusual intracellular but extracytoplasmic niche. No reliable therapy for cryptosporidiosis exists, though the aminoglycoside paromomycin is somewhat effective. We report that paromomycin and the related compound geneticin manifest their major in vitro anti-C. parvum activity against intracellular parasites via a mechanism that does not require drug trafficking through the host cell cytoplasm. We used both normal and transformed aminoglycoside-resistant Caco-2 or MDBK cells in these studies. Timed-exposure experiments demonstrated that these drugs inhibit intracellular but not extracellular parasites. Apical but not basolateral exposure of infected cells to these drugs led to very significant parasite inhibition, indicating an apical topological restriction of action. We estimated intracytoplasmic concentrations of paromomycin, using an intracellular bacterial killing assay, and found that C. parvum infection did not lead to increased paromomycin concentrations compared to those in uninfected cells. Global [3H]paromomycin uptake by Caco-2 cells was approximately 200-fold higher than the estimated intracytoplasmic paromomycin concentration, suggestive of host cell vesicular uptake and concentration (as has been reported with other cell lines). However, preinfection exposure of Caco-2 cells to paromomycin did not result in subsequent inhibition of parasite development, indicating that if exogenous paromomycin enters the infected host cell vesicular compartment, it does not effectively communicate with the parasite. Thus, the apical membranes overlying the parasite and parasitophorous vacuole may be the unsuspected major route of entry for paromomycin and may be of importance in the design and discovery of novel drug therapies for the otherwise untreatable C. parvum.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9673275      PMCID: PMC108441     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  36 in total

Review 1.  A molecular strategy for the study of bacterial invasion.

Authors:  S Falkow; P Small; R Isberg; S F Hayes; D Corwin
Journal:  Rev Infect Dis       Date:  1987 Sep-Oct

Review 2.  Human cryptosporidiosis: epidemiology, transmission, clinical disease, treatment, and diagnosis.

Authors:  J K Griffiths
Journal:  Adv Parasitol       Date:  1998       Impact factor: 3.870

3.  A one pot tritiation of aminoglycoside antibiotics.

Authors:  M L Capmau; B Moreau; F Le Goffic
Journal:  J Antibiot (Tokyo)       Date:  1983-06       Impact factor: 2.649

4.  Semisynthetic aminoglycoside antibiotics. IV. 3',4'-Dideoxyparomomycin and analogues.

Authors:  C Battistini; G Franceschi; F Zarini; G Cassinelli; F Arcamone; A Sanfilippo
Journal:  J Antibiot (Tokyo)       Date:  1982-01       Impact factor: 2.649

5.  Aminoglycoside antibiotics and eukaryotic protein synthesis: stimulation of errors in the translation of natural messengers in extracts of cultured human cells.

Authors:  J M Wilhelm; J J Jessop; S E Pettitt
Journal:  Biochemistry       Date:  1978-04-04       Impact factor: 3.162

6.  Intracellular accumulation of a fluorescent derivative of paromomycin in human fibroblasts.

Authors:  J H Buchanan; S I Rattan; A Stevens; R Holliday
Journal:  J Cell Biochem       Date:  1982       Impact factor: 4.429

7.  Aminoglycoside antibiotic treatment of human fibroblasts: intracellular accumulation, molecular changes and the loss of ribosomal accuracy.

Authors:  J H Buchanan; A Stevens; J Sidhu
Journal:  Eur J Cell Biol       Date:  1987-02       Impact factor: 4.492

8.  [The absorption, excretion and influence on bowel flora of oral paromomycin sulfate (author's transl)].

Authors:  S Iwaki; K Honke; N Nishida; N Taniguchi
Journal:  Jpn J Antibiot       Date:  1981-07

9.  A comparison of endogenous development of three isolates of Cryptosporidium in suckling mice.

Authors:  W L Current; N C Reese
Journal:  J Protozool       Date:  1986-02

Review 10.  Cryptosporidiosis in perspective.

Authors:  S Tzipori
Journal:  Adv Parasitol       Date:  1988       Impact factor: 3.870

View more
  23 in total

1.  Cryptosporidium parvum infection requires host cell actin polymerization.

Authors:  D A Elliott; D J Coleman; M A Lane; R C May; L M Machesky; D P Clark
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

2.  Novel anti-Cryptosporidium activity of known drugs identified by high-throughput screening against parasite fatty acyl-CoA binding protein (ACBP).

Authors:  Jason M Fritzler; Guan Zhu
Journal:  J Antimicrob Chemother       Date:  2011-12-13       Impact factor: 5.790

3.  CpABC, a Cryptosporidium parvum ATP-binding cassette protein at the host-parasite boundary in intracellular stages.

Authors:  M E Perkins; Y A Riojas; T W Wu; S M Le Blancq
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

4.  Validation of IMP dehydrogenase inhibitors in a mouse model of cryptosporidiosis.

Authors:  Suresh Kumar Gorla; Nina N McNair; Guangyi Yang; Song Gao; Ming Hu; Venkatakrishna R Jala; Bodduluri Haribabu; Boris Striepen; Gregory D Cuny; Jan R Mead; Lizbeth Hedstrom
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

5.  A nanotherapy strategy significantly enhances anticryptosporidial activity of an inhibitor of bifunctional thymidylate synthase-dihydrofolate reductase from Cryptosporidium.

Authors:  Anindita Mukerjee; Pinar Iyidogan; Alejandro Castellanos-Gonzalez; José A Cisneros; Daniel Czyzyk; Amalendu Prakash Ranjan; William L Jorgensen; A Clinton White; Jamboor K Vishwanatha; Karen S Anderson
Journal:  Bioorg Med Chem Lett       Date:  2015-04-04       Impact factor: 2.823

6.  Molecular genotyping of human cryptosporidiosis in Northern Ireland: epidemiological aspects and review.

Authors:  C J Lowery; B C Millar; J E Moore; J Xu; L Xiao; P J Rooney; L Crothers; J S Dooley
Journal:  Ir J Med Sci       Date:  2001 Oct-Dec       Impact factor: 1.568

7.  Efficacy of monoclonal antibodies against defined antigens for passive immunotherapy of chronic gastrointestinal cryptosporidiosis.

Authors:  Michael W Riggs; Deborah A Schaefer; Sushila J Kapil; Lise Barley-Maloney; Lance E Perryman
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

8.  Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy.

Authors:  Matthew A Hulverson; Sumiti Vinayak; Ryan Choi; Deborah A Schaefer; Alejandro Castellanos-Gonzalez; Rama S R Vidadala; Carrie F Brooks; Gillian T Herbert; Dana P Betzer; Grant R Whitman; Hayley N Sparks; Samuel L M Arnold; Kasey L Rivas; Lynn K Barrett; A Clinton White; Dustin J Maly; Michael W Riggs; Boris Striepen; Wesley C Van Voorhis; Kayode K Ojo
Journal:  J Infect Dis       Date:  2017-04-15       Impact factor: 5.226

9.  Paromomycin: uptake and resistance in Leishmania donovani.

Authors:  Anupam Jhingran; Bhavna Chawla; Shailendra Saxena; Michael Peter Barrett; Rentala Madhubala
Journal:  Mol Biochem Parasitol       Date:  2008-12-25       Impact factor: 1.759

10.  Targeting a prokaryotic protein in a eukaryotic pathogen: identification of lead compounds against cryptosporidiosis.

Authors:  Nwakaso N Umejiego; Deviprasad Gollapalli; Lisa Sharling; Anna Volftsun; Jennifer Lu; Nicole N Benjamin; Adam H Stroupe; Thomas V Riera; Boris Striepen; Lizbeth Hedstrom
Journal:  Chem Biol       Date:  2008-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.